Collaboration and License Agreements (Additional Information) (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 |
Nov. 30, 2023 |
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
Dec. 31, 2024 |
Dec. 31, 2025 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Collaboration Revenue | $ 54,366 | $ 12,768 | $ 67,544 | $ 120,891 | ||||
| Deferred Revenue | $ 102,261 | 102,261 | 102,261 | $ 111,332 | ||||
| Liabilities Current | 62,046 | 62,046 | 62,046 | 64,212 | ||||
| Milestone Payments | $ 60,000 | |||||||
| Research and Development Target Months | The Company expects that the remaining deferred revenue for the initial targets will be recognized within 11 months. The Company expects that deferred revenue related to replacement targets will be recognized within 25 months. Due to the uncertain nature of the research and development being performed by the Company, it may take longer than anticipated to recognize revenue related to the performance obligations for the initial and replacement targets. Any amounts remaining in deferred revenue will be recognized at the conclusion of the Roche Agreement in October 2028.As of September 30, 2026, potential research, development and regulatory milestone payments that the Company is eligible to receive were excluded from the transaction price as they were fully constrained by uncertain events. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and if necessary, the Company will adjust its estimate of the transaction price. Any additions to the transaction price would be reflected in the period as a cumulative revenue catch-up based on the ratio of costs incurred to the total estimated costs expected applied to the revised transaction price. Sales-based royalties and milestone payments, which predominantly relate to the license, will be recognized if and when the related sales occur. | |||||||
| Collaboration and License Agreement [Member] | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Non-Refundable Upfront Payment | $ 50,000 | |||||||
| Pre-clinical milestones | 16,000 | 16,000 | $ 16,000 | |||||
| Collaboration Revenue | 55,800 | 2,000 | 9,500 | |||||
| Liabilities Current | 7,200 | 7,200 | 7,200 | |||||
| Liabilities Noncurrent | 6,000 | 6,000 | 6,000 | |||||
| Program and Option Exercise Payments | 3,000 | 3,000 | 3,000 | |||||
| One Time Upfront Payment | 13,200 | |||||||
| Collaboration and License Agreement [Member] | Minimum [Member] | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Potential clinical, commercial and sales milestones | 2,000,000 | |||||||
| Collaboration and License Agreement [Member] | Maximum [Member] | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Pre-clinical milestones | $ 172,000 | |||||||
| Roche Agreement [Member] | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Deferred Revenue | 13,162 | 13,162 | 13,162 | $ 22,657 | ||||
| Novartis License Agreement [Member] | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Collaboration Revenue | 180,000 | |||||||
| Total transaction amount | 180,000 | |||||||
| 2024 Novartis License Agreement | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Non-Refundable Upfront Payment | $ 150,000 | |||||||
| Maximum Amount To Be Received | $ 2,100,000 | |||||||
| Collaboration Revenue | 50,000 | 50,000 | 150,000 | |||||
| Clinical Milestone | 50,000 | |||||||
| Revenue, Remaining Performance Obligation, Amount | 0 | 0 | 0 | |||||
| Incremental cost reimbursements recognized as collaboration revenue | 1,200 | |||||||
| Profits And Losses Percentage | 30.00% | |||||||
| Total Transaction Upfront Price | $ 150,000 | |||||||
| 2024 Novartis License Agreement | Minimum [Member] | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Potential clinical, commercial and sales milestones | $ 1,500,000 | |||||||
| 2025 Novartis License Agreement | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Non-Refundable Upfront Payment | 120,000 | |||||||
| Potential pre-clinical, clinical, commercial, and sales milestones | 5,400,000 | |||||||
| Deferred Revenue | 110,200 | 110,200 | 110,200 | |||||
| Liabilities Current | 13,900 | 13,900 | 13,900 | |||||
| Liabilities Noncurrent | 96,300 | 96,300 | 96,300 | |||||
| Program and Option Exercise Payments | $ 180,000 | 180,000 | ||||||
| One Time Upfront Payment | $ 120,000 | |||||||
| Collaboration funds receivable | 60,000 | |||||||
| Milestone Payments | 2,200,000 | |||||||
| Potential sales milestones payment | $ 3,200,000 | |||||||
| Research and Development Target Months | The Company expects that the remaining deferred revenue for the license and research services for a named immunology target and research services for two additional immunology targets to be recognized within 49 months. The deferred revenue related to material right license options will be recognized when Novartis exercises such options rights or at the expiration of the option rights. Due to the uncertain nature of the research and development being performed by the Company, it may take longer than anticipated to recognize revenue related to the performance obligations related to research services. | |||||||
| 2025 Novartis License Agreement | Maintenance [Member] | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Collaboration Revenue | $ 9,800 | $ 2,300 | $ 8,000 | |||||
| One Time Upfront Payment | $ 60,000 | |||||||